- Atezolizumab poised to become a major bladder cancer therapy in the race for FDA approval, following positive Phase II trial results
- The drug will face strong competition in the bladder cancer treatment arena, especially from Bristol-Myers Squibb’s Opdivo and Merck & Co.’s Keytruda, says analyst
Roche’s atezolizumab is poised to become a major bladder cancer therapy in the race for US Food & Drug Administration (FDA) approval, following its promising performance in recent Phase II trials, says an analyst with research and consulting firm GlobalData.
In a potential bladder cancer breakthrough, Roche announced that atezolizumab, an anti-Programmed Death-Ligand 1 (PD-L1) therapy, met its primary endpoint of objective response rate in the Phase II IMvigor 210 study. During the trial, patients with higher PD-L1 expression levels showed better responses to the drug.
According to Cai Xuan, Ph.D., GlobalData’s Analyst covering Oncology and Hematology, this observation, along with similar results for other Programmed Cell Death Protein 1 (PD-1) inhibitors in development for various cancers, opens up a market for companion biomarker tests that can be used to identify patients who would likely benefit from PD-1/PD-L1-targeted therapies.
Xuan says: “Atezolizumab’s Phase II results were preceded by an encouraging Phase Ia trial, during which the drug caused tumors to shrink in 50% of patients previously treated for PD-L1-positive, metastatic urothelial bladder cancer.
“In this trial, 20% of patients made a full recovery, while 57% with the highest PD-L1 expression levels were still alive one year after treatment. The most frequently observed adverse events were fatigue, asthenia, and nausea, affecting 16%, 13% and 11% of patients, respectively.”
The analyst expects atezolizumab to face strong competition in the bladder cancer treatment arena, especially from Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck & Co.’s Keytruda (pembrolizumab). These three drugs have initially been targeted towards patients with locally-advanced and/or metastatic bladder cancer, with the possibility of expanding to multiple indications within the bladder cancer setting in the future.
Xuan continues: “With regards to future indications, Roche currently has a broader development program for atezolizumab in bladder cancer, with the IMvigor 211 Phase III trial evaluating the drug in comparison with standard-of-care chemotherapy in patients with relapsed urothelial bladder cancer.
“Additionally, the IMvigor 010 Phase III trial will evaluate atezolizumab as an adjuvant therapy in early-stage, PD-L1-positive, muscle-invasive bladder cancer patients, who are at risk of recurrence. The potential to expand into multiple indications will make this drug an important player in a wave of long-awaited bladder cancer treatment innovation.”
– Comments provided by Cai Xuan, Ph.D., GlobalData’s Analyst covering Oncology and Hematology.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.For more information, please contact our Press Office on +44 (0)1204 543 537 or at email@example.com.
Barbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide.